Home / Learn / Immunotherapy / About the Institute

About the Institute

In 2015, ACCC launched the Institute for Clinical Immuno-Oncology, the first initiative to guide the multidisciplinary care team’s adoption of immuno-oncology (IO) in community cancer settings across the country. Since that time, IO has advanced at a rapid pace—and so has our Institute!

The Association of Community Cancer Centers (ACCC) Immuno-Oncology Institute is the leader in optimizing the delivery of cancer immunotherapies for patients by providing clinical education, advocacy, research, and practice management solutions for multidisciplinary cancer care teams across all healthcare settings.The Institute provides a platform for dynamic, multi-directional learning to:

  • Contribute to the growing body of community experience with new and emerging therapies
  • Connect the wider community with thought leaders in immuno-oncology
  • Provide access to practical, data-driven resources
  • Engage stakeholders in dialogue on practice innovations and implementation of immuno-oncology therapies
  • Support cancer patient access to immunotherapy treatment

The ACCC Immuno-Oncology Institute is guided by an expert multidisciplinary Executive Committee.

Our Supporters

logo-EMDSerono-200x80Gilead Kite Logo


The ACCC Immuno-Oncology Institute is supported by Bristol-Myers Squibb (charitable donation); EMD Serono; Kite, a Gilead Company; and Merck & Co, Inc (educational grant).